Location: Endemic Poultry Viral Diseases Research
Project Number: 6040-32000-073-07-R
Project Type: Reimbursable Cooperative Agreement
Start Date: Apr 1, 2015
End Date: Mar 31, 2019
1. To further evaluate protection conferred by rLS/IBVS2 prime and Mass boost vaccination regime against challenge with IBV showing dissimilar S1. 2. To evaluate protection conferred by simultaneous combined vaccination with rLS/IBVS2 (previously developed) with a Mass attenuated vaccine at 1 day of age. 3. To develop and evaluate protection against IBV conferred by vaccination with a new rLS vectoring an IBV S2 representing a consensus of U.S. IBV genotypes (rLS/IBV.S2CM). 4. To develop and evaluate rLS vectoring the S2 gene of IBV 4/91.
We propose to use recombinant Newcastle disease virus (rNDV) LaSota strain as vector to express an infectious bronchitis virus (IBV) S2 representing a consensus of U.S. IBV genotypes, and the S2 of IBV 4/91 strain. Resistance conferred by rNDV expressing distinct IBV S2 proteins will be evaluated by protection against challenge [differential -clinical signs, -viral load (qRT-PCR), and –histopathology] and immunogenicity [characterization of B and T cell responses (ELISPOT, cytokine expression, flow cytometry) and antibody responses (ELISA)].